Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Deferred Taxes (2020 - 2025)

Catalyst Pharmaceuticals' Deferred Taxes history spans 6 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 276.56% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $6.8 million, down 27.05%, while the annual FY2025 figure was $6.8 million, 27.05% down from the prior year.
  • Deferred Taxes reached $4.5 million in Q4 2025 per CPRX's latest filing, up from -$2.4 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $13.9 million in Q3 2023 to a low of -$2.7 million in Q4 2021.
  • Average Deferred Taxes over 5 years is $990100.0, with a median of -$850000.0 recorded in 2022.
  • Peak YoY movement for Deferred Taxes: crashed 269.03% in 2021, then skyrocketed 1592.83% in 2023.
  • A 5-year view of Deferred Taxes shows it stood at -$2.7 million in 2021, then skyrocketed by 53.19% to -$1.3 million in 2022, then skyrocketed by 31.28% to -$883000.0 in 2023, then plummeted by 189.35% to -$2.6 million in 2024, then soared by 276.56% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Deferred Taxes are $4.5 million (Q4 2025), -$2.4 million (Q3 2025), and $2.4 million (Q2 2025).